Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.57 USD
Change Today -0.039 / -6.39%
Volume 271.3K
ONCY On Other Exchanges
As of 4:30 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1167 Kensington Crescent, NW

Suite 210

Calgary, AB T2N 1X7


Phone: 403-670-7377

Fax: 403-283-0858

Oncolytics Biotech Inc., a development stage company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. REOLYSIN The company’s potential product for human use, REOLYSIN, is developed from the reovirus. This virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. The company’s clinical program includes clinical trials which it sponsors directly along with third party clinical trials. In 2014, the U.S. National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) and the National Cancer Institute of Canada (NCIC) were sponsoring part of the company’s clinical trial program. Business Strategy The company’s business strategy is to develop and market REOLYSIN in an effective and timely manner. It intends to achieve business strategy by focusing on these key areas: develop REOLYSIN by continuing to progress the product through clinical trial program assessing the safety and efficacy in human subjects; establish collaborations with experts to assist with scientific and clinical developments of this new potential pharmaceutical product; implement strategic alliances with selected pharmaceutical and biotechnology companies and selected laboratories; utilize broadening patent base and collaborator network as a mechanism to meet strategic objectives; and develop relationships with companies that could be instrumental in assisting the company to access other innovative therapeutics. Patents and Trade Secrets The company has approximately 400 issued patents including 56 issued U.S. patents. Regulations The company’s toll manufacturers are subject to periodic inspection by the United States Food and Drug Administration, the United States Drug Enforcement Administration (DEA), and other domestic and foreign authorities where applicable, and must comply with current Good Manufacturing Practices regulations. History Oncolytics Biotech Inc. was founded in 1998. The company was incorporated in 1998 under the Business Corporations Act (Alberta).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCY:US $0.57 USD -0.039

ONCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCY.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at